chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Information has been received from a nurse in a physician's office concerning a female patient "in her 20's" who on an unspecified date was vaccinated with HPV rLi 6 11 16 18 VLP vaccine (yeast).  It was reported that the patient "fainted" after being given HPV rLi 6 11 16 18 VLP vaccine (yeast) (date unknown).  At the time of this report, the outcome of the event was unknown.  Additional information has been requested.
Patient complaining of swollen left arm where pneumonia vaccine administered. Site was also red & warm, patient stated he worked out with weights after being injected on 9-13-12. I spoke to patient again today at 5:50 pm & he stated arm does not hurt & swelling went down.
Difficulty breathing, difficulty swallowing, labor breathing. 0.3 epi and 25 mg of Benadryl given.
Pt c/o dizziness and feeling faint at approx 5:13, pt received vaccine at 5:00pm.  Nurse instructed pt to lay down and elevated feet with nearby chair. Cold compress applied to forehead. Notified NP.  Upon laying down pt stated he felt relief. Pt stated "I just felt a sudden rush but I feel better now" Pt instructed to continue to lay down for a few minutes, and as he feels better he may sit up, and then eventually rise to the chair.  Pt tolerated sitting up at 5:23pm. Nurse continued to monitor pt while he was sitting. Pt continued to state he was feeling better. Denies shortness of breath. Pt speaking and talkative to nurse, no signs of respiratory distress noted.
Joints aching 06/04 x 1/1/2 weeks. Headache/vomiting 06/08 x 1. Fever 06/09 x 2d, rash 06/10 x 4d.
A pediatric dose of Hep B (Engerix B) was given to an adult; A pediatric dose of Hep B (Engerix B) was given to an adult; This case was reported by a nurse via sales rep and described the occurrence of underdose in a adult female patient who received HBV (Engerix B pediatric) (batch number 39A3L, expiry date 23rd February 2024) for prophylaxis.   On 10th May 2022 17:15, the patient received Engerix B pediatric. On 10th May 2022 17:15, unknown after receiving Engerix B pediatric, the patient experienced underdose and adult use of a child product. On an unknown date, the outcome of the underdose and adult use of a child product were unknown.   Additional Information: GSK Receipt Date: 11-MAY-2022 Reporters comment: The patient was 44 years of age at the time of reporting. A pediatric dose of Engerix B was given to an adult patient instead of the adult dose of Engerix B.  The patient had been informed and was scheduled next month from the date of reporting to receive the correct adult dose. The reporter consented to follow up. Additional supportive information: A pediatric dose of Engerix B was given to an adult patient instead of the adult dose of Engerix B, which led to underdose and adult use of a child product.
Pt presented to the ER on 2/26 with hemorrhagic CVA basal ganglia, left sided hemiparesis, dysarthria, WBC elevated to 19,000, platelets elevated 568,000, new anemia, CRP markedly elevated
sore left side of neck ,pain with trying to turn head approximately 5 and half hours later.applied hea ting pad to left side of neck during the night approximately 10  to 12 hrs.
This case was reported by a consumer via interactive digital media and described the occurrence of suspected vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis. On an unknown date, the patient received Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant), shingles and pain. On an unknown date, the outcome of the vaccination failure was unknown and the outcome of the shingles and pain were not recovered/ not resolved. It was unknown if the reporter considered the vaccination failure, shingles and pain to be related to Shingles vaccine. Additional details were provided as follows: The patient had reported for him/herself. The age at vaccination was not reported. After receiving Shingles vaccine, the patient still got shingles. The patient stated that, shingles were very painful. This case was considered as suspected vaccination failure, since the details regarding the completion of the primary immunization, time to onset for event and laboratory confirmation of shingles were not provided.
pt recv vax 1998 or early 1999 & 1/99 pt devel influenza;the local hlth dept told MD that an H3N2 strain was circulating in the area;exact strain was not provided;
"Since receiving 1st Pfizer vaccine 8/21/21, episodes of anterior chest pain.   3 visits to Urgent Care/ ER within the first 3 weeks post vaccination with SOB.  Treated with steroids.       Since 9/21, still SOB particularly at night.   Daily bilateral constant anterior chest discomfort.   Episodes of right sided sharp chest pain, worse when reaching with right arm.  Poor stamina.   Sometimes, has epiosodes of thumping of the heartbeat.  Underwent cardiac cath 2/22.  Minimal irregularities.  Lipid medication recommended.  Rosuvastatin 10 mg started 2/22. "
On dec 29 I began fever, chills and bad headache. Tested negative for covid and flu. Also fatigue.  Then dizzy and just didn?t feel good. Tested negative again on January 4. But still dizzy and fatigue.
vaccine used past the 12 hour window of use after vial punctured. Stored in fridge entire time and cleaned between each use with alcohol.  Pt contacted and no adverse reaction, pt states no problems
Patient had redness on the lower arm away from the injection site that was very painful and red.  She said it seems to be getting better but almost had to go to doctor for the pain. She said she has taken ibuprofen and will apply cold compress but it seems to be getting better. She will update us in the next few days if it continues.
diarrhea; Feeling lousy; 3x3 rash on left arm right above the injection site; A spontaneous report was received from a consumer concerning a 59-year old, female patient who is a nurse and experienced feeling lousy, 3x3 rash on left arm right above injection site, and diarrhea.   The patient's medical history was not provided. Concomitant medications reported included acetylsalicylic acid, diltiazem, sitagliptin, escitalopram oxalate, esomeprazole magnesium, simvastatin, ezetimibe, and losartan potassium.   The patient received their first of two planned doses of mRNA-1273 (lot #011I-20A) intramuscularly in the left arm for prophylaxis of COVID-19 infection on 22 Dec 2020.    On 23 Dec 2020, the patient reported waking up feeling lousy, with diarrhea, and a 3x3 rash on her left arm above the inject site that was not itchy, spreading or getting bigger. No treatment was given in response to the events.    Action taken with mRNA-1273 in response to the events was unknown.    The outcome for the events, feeling lousy, 3x3 rash on left arm right above injection site, and diarrhea, were unknown.   The reporter did not provide an assessment for the events, feeling lousy, 3x3 rash on left arm right above injection site, or diarrhea.; Reporter's Comments: This case concerns a 59 year old female patient , who experienced the unlisted event of  diarrhea and the listed events of feeling lousy and a 3x3 rash on her left arm above  The events occurred  one day after first dose of IP. No action was informed regarding the second dose of IP.  The reporter did not provide event´s outcome or causality assessment regarding the IP. The event was considered related to the event due to temporal association. Further details are requested to reporter.
Site: Pain at Injection Site-Medium, Site: Redness at Injection Site-Medium, Site: Swelling at Injection Site-Medium, Additional Details: The injections site is raised , swelling, feels warm.  The swelling is down to inside of elbows
Initial report received on 21 September 2007 from a physician.  An 11 year-old female patient, had received an intramuscular dose of Menactra; lot number U2402AA, in the left deltoid on 18 September 2007.  Immediately following the vaccination, the patient experienced dizziness and was laid down on an examination table.  The patient's pulse rate and skin color did not change during this time.  The dizziness lasted less than five minutes, and the patient recovered.  The reporter for this case is the same as for case 2007-02753.
This spontaneous report as received from a healthcare worker refers to a patient of unknown age. On 24-APR-2013 the patient was vaccinated with a dose of VAQTA 50/1.0 U/ML lot # 0628AE, expiration 26-JAN-2015 (dose and route unknown). The Healthcare worker reported that VAQTA had multiple excursions from 20-FEB-2013 to 13-MAY-2013. The lowest temperature the vaccines reached was 24F. The total time of hours for the excursions was 253 hours. No adverse effect reported. This is one of several reports received from the same source. Additional information has been requested.
Developed immediate left arm pain that worsened to rotator cuff injury and decreased range of motion at left shoulder. Patient went to see orthopedic physician on Jan 29, 2021 and started physical therapy Feb 2, 2021. Currently physicl therapy is ongoing.
Concerned pancreatitis may be related to his Covid vaccine.  He had his first vaccine 3/11/2021, followed by colonoscopy on 3/12/2021 (polypectomy x 2 from sigmoid colon) with complaints of abrupt onset of upper abdominal pain 3/17/2021 diagnosed as pancreatitis. He found an article discussing association of COVID-19 vaccine with pancreatitis.  Hospitalized 3/17-3/24/2021 with acute pancreatitis,  No EtoH use, smoking, hyperTG, hypercal, IGG4 normal.  No signs of gallstone disease based on labs or right upper quadrant ultrasound/CT scan. Etiology was presumed 2/2 HCTZ/Losartan and possibly by bowel prep. Tolerated diet and eventually was discharged.  Readmitted 4/5-4/19 with acute necrotizing pancreatitis with evolving peripancreatic fluid collections.
Dizziness and nausea.  I was prescribed Meclizine and Zolfran.  I just went to get medicine.
allergic reaction; This is a spontaneous report received from a contactable reporter(s) (Physician) from medical information team, Program ID. The reporter is the patient.  A male patient received rsv vaccine prot.subunit pref 2v (ABRYSVO), as dose number unknown, single (Batch/Lot number: unknown) for immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: HYPERSENSITIVITY (non-serious) with onset Sep2023, 2 weeks after the suspect product(s) administration, outcome "not recovered", described as "allergic reaction".  Additional information: The specialty of patient (the reporting physician) was allergy and Immunology. He was administered Abrysvo, after 2 weeks he experienced an allergic reaction, and had this now for a month. He asked how long will the reaction last?  The information on the batch/lot number for rsv vaccine prot.subunit pref 2v, rsv vaccine prot.subunit pref 2v  has been requested and will be submitted if and when received.
Patient was administered partial dose to right arm. As advised per medical director, following cdc guidelines, single dose administered to left arm. Patient observed for 15 minutes.
I experienced a breakthrough case of COVID-19 with fast heart rate, anxiety, tiredness and adrenaline rushes.
reports feeling tired after her first Moderna Covid-19 vaccine.; This spontaneous case was reported by a patient and describes the occurrence of FATIGUE (reports feeling tired after her first Moderna Covid-19 vaccine.) in an 83-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. L029L20A, 0012A21A and 037C21A) for COVID-19 vaccination.     No Medical History information was reported.   On 26-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 24-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 10-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 26-Jan-2021, the patient experienced FATIGUE (reports feeling tired after her first Moderna Covid-19 vaccine.). At the time of the report, FATIGUE (reports feeling tired after her first Moderna Covid-19 vaccine.) outcome was unknown.        mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) dosing remained unchanged.       No Concomitant product use was reported.  The patient received their first Moderna Covid-19 vaccine on 26-Jan-2021 and reported feeling tired after the first Moderna Covid-19 vaccine. The patient received their second dose of Moderna vaccine on 24-Feb-2021 and reported no adverse reactions or side effects to the second dose. The patient received their first booster dose on 10-Nov-2021 and had no adverse reactions or side effects after the first booster dose.  No treatment information was provided.
This spontaneous report as received from a registered nurse refers to a patient of unknown age and gender. On 02-AUG-2011 the patient was vaccinated with the first 0.5ml dose of GARDASIL (lot# and strength unspecified), intramuscularly. On 28-JUL-2014 the patient was vaccinated with the second 0.5ml dose of GARDASIL (lot# and strength unspecified), intramuscularly. No adverse effects reported. The outcome of the event was unknown. Additional information is not expected as the reporter did not want to be contacted.
Over the course of the last two years, patient has realized that he is losing memory of certain events, developing both long term and short term memory problems.  Coupled with severe joint problems in both the knees and wrists, ie cracking, poping, and soreness.  Lot# FAV041 Left Arm
Patient's family noticed the patient was unable to speak, was severely confused and had R arm weakness.  Patient was brought to ER and was observed to be globally aphasic and had left gaze palsy.  Lask known well was 2200 on 1/27.  HCT (-) but still not a candidate for tPA.  BP in ER was 200/130.  Cardene started. Patient was eventually intubated.  CT angiogram (-) and MRI (-).  Patient is now only responsive to painful stimulation and only has flicker of muscle movements in all 4 extremities.
Information has been received from an employee in a physician's office concerning a 5 year old white male with no known allergies, birth defects, or medical conditions who on 30-MAR-2001 was vaccinated SC with a first dose of Varivax in another physician's office. On 05-MAR-2006 the patient developed varicella lesions "also in mouth." Medical attention was not sought. Subsequently the patient recovered. Additional information is not expected.
Approx 20 minutes after injection, redness right inner forearm radiating to right deltoid, itching. Given ice and hydrocortisone cream for area. Called employer - pt fine.
Information has been received from a physician, for GARDASIL, a Pregnancy Registry product, concerning a 25 year old female patient with no pertinent medical history who in approximately March 2009, was vaccinated with a first dose of GARDASIL (lot number, route and site not reported). There was no concomitant medication.  Subsequently the patient determined to be pregnant. The patient's menstrual period was not reported. The patient experienced a spontaneous miscarriage on an unspecified date. The patient had sought unspecified medical attention. At the time of report, the patient had recovered on an unspecified date. The physician felt that spontaneous miscarriage was not related to therapy with GARDASIL. Upon internal review, spontaneous miscarriage was considered to be an other important medical event. Additional information has been requested.
Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; This spontaneous case was reported by an other health care professional and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) in a 74-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 019B21A and 014M20A) for COVID-19 vaccination.     No Medical History information was reported.   On 28-Mar-2021 at 3:28 PM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 28-Feb-2022 at 3:19 PM, received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to .5 milliliter. On an unknown date, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Age of patient was reported as 74.19 for dose administered on 28-Feb-2021 and 74.26 for dose administered on 28-Mar-2021.  No concomitant medications were reported.  Batch number 019B21A administered on 28-Mar-2021 with temperature 35 degrees Fahrenheit from 10:00AM. This vial was moved to fridge on 23-Mar-2021 and beyond use date for the vial was reported as 22-Apr-2021. Product moved to clinic on 27-Mar-2021.  Batch number 014M20A administered on 28-Feb-2021 with temperature 27 at 09.00 AM and 26 at 01.00 PM. This vial was moved to fridge on 24-Feb-2021 and beyond use date for the vial was reported as 26-Mar-2021. Product moved to clinic on 27-Feb-2021.  Vial was in cooler storage and was not in frozen storage during high-pace COVID-19 vaccination at around 2021. Vials were only punctured right before administration. Vaccines were not frozen at time of administration. It was reported that each time a vial was put into a cooler, sometimes there was a period of 1 hour or 1 hour and a half approximately, when temperature data logger registered a temperature of 34- or 35-degree Fahrenheit. Temperature recordings were taken using a traceable temperature monitor at every hour.  No treatment medications were reported.
COVID-19; COVID-19; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP) from product quality group. The reporter is the patient.  A 63-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 19Jan2021 as dose 1, single (Lot number: EL9261), in left arm, on 09Feb2021 as dose 2, single (Lot number: EN5318), in left arm and on 27Sep2021 as dose 3 (booster), single (Lot number: FC3592) at the age of 61 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Chronic lymphocytic leukaemia" (unspecified if ongoing). There were no concomitant medications. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Unknown results, notes: Treatment of COVID-19. Therapeutic measures were taken as a result of vaccination failure, covid-19.  Addition information: Other medication in 2 weeks was none. Known allergies were none.
Sore arm, one year later breakthrough Covid. Sore throat, congestion took home test came back positive.
Neuroretinitis, right eye, with symptoms noticed 1 week after vaccination.  Vision OD decreased to 20/200 associated with optic nerve head edema and macular star exudates. No afferent pupillary defect.  OS normal exam.  Empirically Rx'd 3/31/2021 with azithromycin 500mg once, then 250mg for 4 days.  Vision improved to 20/50 by 4/9/2021 with decreased optic nerve edema, but persistent macular star.  Patient declined 2nd dose of COVID vaccine.  2nd blood draw for cat scratch serology drawn 4/9/2021 with result  pending.
Fainted on day 2. Woke up with a bruise under eye. Extreme pain in entire chest, shoulders. No headaches,  no fever. Did not injure myself during fainting spell. Pain in chest and arms, occasional  chills continued for 2 weeks solid. I needed to take pain relief round the clock. Pain when sneezing or coughing, continuing for 2 weeks. Prior to the 2nd shot, I would describe myself as in very good condition.  After, very weak physical condition. I feel like I need to recover from this shot.
COVID-19 positive test, then symptoms appeared. Symptoms: body aches, joint pain, extreme exhaustion, lower limb edema, headache, NO fever.
Right arm cold feeling progressed to neck and legs.  Tried to return to facility after 25 minute interval after the vaccination. Then felt faint and called 911 who responded reported passed out while on 911 dispatch.
12 hours post vaccine, developed body aches, fever, severe arm and underarm pain radiating over to chest. Seen at clinic, then sent to ED for chest Ultrasound- but was not done. COVID tested- results-negative.  Treated with Acetaminophen and Ibuprofen, rest off work x several days.  Cleared to return to work on 1/21/21.
severe muscle aches, elevated BP, chills, fever, paleness, weakness, dizziness, elevated blood sugars. still occurring dizziness.  Follow up received states - I don't have this information. I got the vaccine in another county on 1/9/10.
Patient received first dose of  Pfizer. Patient received the 7th dose of  the vaccine vial.
Redness and swelling and itching noted to right deltoid on 4/25/2007. Parents took child to ED Patient received IV fluids and a (medication) per father. Ice packs applied.
12:40 pm vaccine received 1600 chills started 1800 chills worsened, palpitations 2200 body aches, nausea, rigors 0030 severe nausea, palpitations, feeling faint, fever 100.5 0230 headache  0600 nausea stopped, palpitations stopped  by Wednesday evening all but body aches and headaches resolved Thursday persistent body aches, on and off stabbing headache continued, almost passed out while walking x 1, chest vibrations in one spot - but able to work with Tylenol by Friday 100% back to normal
Dizziness, vertigo, brain fog, fatigue, arm soreness started 1-2 days after second shot. No medication was taken and symptoms resolved after 2 weeks.  Lymph nodes in my neck were so swollen I had trouble breathing and this started 3 weeks after second shot. I took oral steroids for 5 days and it resolved.
Information has been received from a registered nurse (RN) concerning an elementary aged child who was vaccinated with a dose of Varivax. The RN reported that in February 2006, the patient developed breakthrough chickenpox which was considered to be a light, mild case. Unspecified medical attention was sought. At the time of this report, the outcome was unknown. Additional information has been requested.